News: Summit Life Sciences has been officially selected as a winner of the prestigious Red Herring 100 Asia 2007 awards

Summit is a Chinese life sciences company that develops, produces and markets world's revolutionary medical materials and devices for treatment of damaged tissue or organs. It is not only the market leader in China, but also one of the fastest growing and earliest profitable players in the global regenerative medicine industry. NormalGen™, a surgical patch used in neurosurgery, has achieved remarkable market acceptance. By May 2007, over 10,000 patients have been successfully treated with the product in more than 150 major Chinese hospitals. Sales revenue has also grown much faster than anticipated with a QoQ growth rate of more than 80%. According to a recent survey produced by the company, NormalGen™ is the best product in market and has successfully competed with products from large establishments such as Synovis and Johnson & Johnson from the U.S. The management team is mature, focused and has demonstrated ability to manage critical issues in technology, clinical trials and regulatory approvals. In addition to develop a world leading technology platform with less than 10% funding compared to in the developed countries, The management also established a direct sales and agents combined distributing network covering 26 provinces in China.